Biodesix, Inc.

NASDAQ:BDSX

Medical - Diagnostics & Research

Healthcare
$8.40 +13.40%

+$2.04 today

Market cap
$68.38M
Beta
0.59
P/E (TTM)
-5.2
EPS (TTM)
-$3.31
52W Low $5.00High $20.21

Volume 0.17M

Average 0.06M

BDSX Pre-Tax Margin

Income before tax as a percentage of revenue.

Biodesix, Inc.NASDAQ: BDSX

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin widens to -30.5%

Pre-tax margin was -30.5% in Q1 FY2026, up 31.3 pp from a year earlier. On a trailing-twelve-month basis it was -33.3%, up 21.0 pp year over year. Over 3 fiscal years it widened by 131.4 pp.

Context

  • Pre-tax margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-30.5%-16.7 pp QoQ
Last fiscal yearDec 2025
-39.8%+20.3 pp YoY
LTMMar 2026
-33.3%+21.0 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+31.3 pp——
1 year+20.3 pp——
3 years+131.4 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-39.8%
Year-over-year change
+20.3pp

Pre-Tax Margin vs competitors

How BDSX compares with its peers on the latest reported figures

  • BDSX's LTM Mar 2026 pre-tax margin of -33.3% is the highest of the 3 companies compared; the peer median is -45962.3%.
  • Its year-over-year change of +21.0 pp is the lowest of 3, against a peer median of +104623.4 pp.
  • Over three fiscal years its change of +131.4 pp compares with a peer median of -84566.8 pp.
BDSX Competitors Peer median
Pre-Tax Margin for BDSX and competitors
Company Period LTM level YoY 3-year change
BDSXBiodesix, Inc.LTM Mar 2026-33.3% +21.0 pp+131.4 pp
XLOXilio Therapeutics, Inc.LTM Mar 2026-58.5% +527.0 pp—
INMBINmune Bio, Inc.FY2025-91866.0% +208719.7 pp-84566.8 pp
OKUROnKure Therapeutics, Inc.FY2025— ——
PDSBPDS Biotechnology CorporationFY2025— ——
Peer median (excluding BDSX) -45962.3%+104623.4 pp-84566.8 pp

Competitors are the stored peer set for BDSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue54.51M38.21M49.09M71.32M88.5M
Cost of Revenue30.52M14.15M13.01M15.57M16.72M
Gross Profit23.99M24.06M36.08M55.75M71.78M
Gross Margin44.0%63.0%73.5%78.2%81.1%
Research & Development12.79M13.1M9.99M9.56M12M
Selling, General & Admin50.52M61.46M67.39M80.45M87.55M
Operating Expenses64.93M74.65M77.42M90.25M99.55M
Depreciation & Amortization3.18M5.84M5.51M5.46M5.6M
EBITDA(35.47M)(51.53M)(37.1M)(29.22M)(21.95M)
EBITDA Margin-65.1%-134.9%-75.6%-41.0%-24.8%
Operating Income(40.94M)(50.59M)(41.34M)(34.5M)(27.77M)
Operating Margin-75.1%-132.4%-84.2%-48.4%-31.4%
Interest Income00000
Interest Expense4.51M8.07M9.54M8.26M7.72M
Other Income / Expenses(2.22M)(14.86M)(10.8M)(8.43M)(7.5M)
Income Before Tax(43.16M)(65.45M)(52.15M)(42.93M)(35.27M)
Pre-Tax Margin-79.2%-171.3%-106.2%-60.2%-39.8%
Income Tax Expense00000
Net Income(43.16M)(65.45M)(52.15M)(42.93M)(35.27M)
Net Margin-79.2%-171.3%-106.2%-60.2%-39.8%
EPS (Basic)(31.60)(31.00)(12.80)(6.60)(4.67)
EPS (Diluted)(31.60)(31.00)(12.80)(6.60)(4.67)
Weighted Avg Shares1.37M2.11M4.11M6.48M7.55M
Weighted Avg Shares (Diluted)1.37M2.11M4.11M6.48M7.55M

Biodesix, Inc.

NASDAQ:BDSX

Intrinsic Alpha fair value

Locked

Current Price

$8.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.